DaunoXome data presented at international cancer meeting.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003630:Daunorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000627:therapeutic use; D004337:Drug Carriers; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000209:etiology; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D001761:Bleomycin; D014747:Vinblastine; D004317:Doxorubicin; D003630:Daunorubicin